THE EFFECT OF LIPOSOMAL EPIGALLOCATECHIN GALLATE AND METOCLOPRAMIDE HYDROCHLORIDE CO-ADMINISTRATION ON EXPERIMENTAL MIGRAINE

ADRIANA ELENA BULBOACĂ 1, ALINA PORFIRE 2, CRISTINA BARBĂLATĂ 2, SORANA D. BOLBOACĂ 3*, CRISTINA NICULA 4, PAUL MIHAI BOARESCU 1, IOANA STĂNESCU 5, GABRIELA DOGARU 6

*corresponding author: sbolboaca@umfcuj.ro

“Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

1Department of Pathophysiology
2Department of Pharmaceutical Technology and Biopharmaceutics
3Department of Informatics and Biostatistics
4Department of Ophthalmology
5Department of Neurosciences
6Department of Medical Rehabilitation

Abstract

Epigallocatechin gallate (EGCG) has been intensively studied for its anti-oxidative, anti-inflammatory and anti-nociceptive effects. Our study aimed to assess the beneficial effect of liposomal EGCG (L-EGCG) co-administered with metoclopramide (MC) on oxidative stress and pain in experimental migraine induced by i.p. nitroglycerin (NG) administration in rats. Five groups of randomly divided rats (7/group) were investigated: control (C, group 1) with i.p. administration of saline solution, NG control group (group 2), NG+MC (group 3), NG+MC+EGCG group (group 4), and NG+MC+L-EGCG (group 5). The nociception was appreciated by the formalin test and the oxidative stress/anti-oxidant status by serum tests. MC alone significantly improved the nociception process and the oxidative stress parameters but not the antioxidative status. Adding EGCG to MC significantly reduced the oxidative stress and antioxidant status together with decreasing of nociception, with better results for L-EGCG.

Keywords: experimental migraine, epigallocatechin gallate, oxidative stress, liposomes

Introduction

Migraine is one of the disabling disorders and acute or prophylactic treatment of migraine attack is still under research [35]. Improving the medication strategies is important since existing treatments have their limitations: triptans can be improper for patients with cardiovascular pathologies, non-steroidal anti-inflammatory drugs (NSAID) have various contraindications and calcitonin-gene related peptide (CGRP) receptors antagonists, the newly approved therapies, have a high efficacy only as a prophylactic treatment [24, 39]. Oxidative stress proved an important contributor to migraine pathophysiology; therefore, reducing the oxidative stress intensity associated with migraine attack could improve the existing migraine treatments [9]. Oxidative stress molecules can contribute to the initiation and persistence of migraine pain, and even to the transformation in chronic pain, by influencing the nociceptive mechanism [3]. Metoclopramide (MC) is one of the choice medications for migraine attack, being widely used due to its ability to reduce the pain and to suppress one of the most critical migraine associated symptom, i.e. nausea, having comparable effects with triptans [2].
One of the most important constituents released during a migraine attack, nitric oxide (NO) is used as a molecule able to induce experimental migraine and hyperalgesia in rats, by nitroglycerin administration (NO donor) [31]. Natural compounds with anti-inflammatory and antioxidant properties are intensively studied [23, 28]. Among natural compounds, curcumin has previously been studied in addition to sumatriptan treatment, naproxen treatment or alone and proved efficient in experimental migraine due to its anti-oxidant and anti-inflammatory properties [4-6]. Epigallocatechin gallate (EGCG), another natural compound from green tea extracts, contains in its molecule a flavanol core and two gallatechol rings that are responsible for trapping the free radicals from the environment [21]. The EGCG antioxidant activity is mostly related to hydroxyl and galloyl groups inside the structure of catechins. Thus, EGCG was proved to have more efficient antioxidant properties than vitamin C and E [13, 33]. Moreover, EGCG is already demonstrated to be able to cross the blood-brain barrier and to exert its activity in brain parenchyma [27]. The nanof ormulation of natural compounds can facilitate their pharmacological properties in order to offer a better efficiency [38]; EGCG nanoformulation could bring new benefits by improving its therapeutical properties [12]. The aim of this study was to investigate the improvement of nociception process, the changing of oxidative stress parameters (malondialdehyde, nitric oxide and total oxidative stress levels in plasma) and of the antioxidative capacity (assessed by measuring of catalase level and total antioxidant capacity of plasma) by co-administration of liposomal-EGCG and MC in an experimental migraine model induced by nitroglycerin rats.

Materials and Methods

Materials. Metoclopramide hydrochloride was purchased from Sigma-Aldrich (St Louis, MO, USA), and nitroglycerin from PubChem (Germany). The materials used for liposomes preparation were: (−) epigallocatechin gallate (EGCG) from green tea (Sigma-Aldrich, Germany), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and N-(carbonyl-methoxy(polyethyleneglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine Na-salt (MEG-2000-DSPE) (Lipoid GmbH, Germany) and cholesterol (CHO) from sheep wool (Sigma-Aldrich, Germany). All solvents and reagents were of analytic grade purity. The reagents used to quantify the oxidative stress and antioxidant status were procured from Sigma-Aldrich, Germany.

Experimental model

All animal procedures were performed after the approval of the Ethics Institutional Committee and were authorized by the Medicine and National Veterinary authority. For the experimental model, 35 Wistar-Bratislava male rats were used (procured from the Animal Department, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania). The animals weighing 200 - 250 g were randomly divided into 5 groups (7 animals per each group) and were kept in polypropylene cages in light-dark regime, at a constant temperature (24 ± 2°C) and humidity (60 ± 5%). The animals were fed by free access with standard pellets (“Cantacuzino” Institute, Bucharest, Romania) and had free access to water.

One group was the control group (C, group 1) and received only i.p. saline solution (0.9% sodium chloride). For the other four groups, migraine was induced by i.p. administration of NG solution. 30 min after NG administration, 3 of the groups received another i.p. injection consisting in MC solution (NG+MC group, group 3), MC and EGCG solution (NG+MC+EGCG group, group 4), MC and L-EGCG (NG+MC+L-EGCG group, group 5), respectively. One group was not treated after NG administration and was considered the positive control group (NG, group 2). Each medication was dissolved in saline solution (0.9% sodium chloride) and the volume administered i.p. was 1 mL [6]. The NG was administered in a dose of 1 mg/100 g bw [6] and the MC in a dose of 1 mg/kg bw [7]. EGCG, in saline solution or in liposomal form, was freshly prepared and was administered in a dose of 2.5 mg/kg bw, i.p. [32].

Preparation and physicochemical characterization of EGCG-loaded liposomes

Liposomes were prepared using a modified film hydration method [29, 36]. Lipid bilayer components in a concentration of 70 mM (DPPC:MPEG-2000-DSPE:CHO = 4.75:0.25:1 molar ratio), were dissolved in ethanol in a round-bottomed flask. The solvent was evaporated at 45°C under reduced pressure, and the resulted lipid film was hydrated at the same temperature with EGCG solution in ultrapure water, pH = 5.00. The liposomal dispersion was subsequently extruded through polycarbonate membranes with the final pore size of 200 nm, using LiposoFast LF-50 equipment (Avestin Europe GmbH, Germany). The un-encapsulated EGCG was removed by dialysis, using Slide-A-Lyzer cassettes with a molecular weight cut-off of 10 kDa.

The total amount of liposomal-loaded EGCG was determined by using a spectrophotometric method based on the reaction with Folin-Ciocalteu (F-C) reagent Merck (Germany) [30]. For this, the liposomal dispersion was diluted with methanol 1:10 (v/v) and the absorbance was measured using a UV-VIS spectrophotometer (Spectord 200 Plus, Analytik Jena, Germany). Liposomal size and polydispersity were determined by dynamic light scattering method with a scattering angle of 90°, and zeta potential by laser Doppler electrophoresis. Both analyses were performed using
a Zetasizer Nano ZS analyser (Malvern Instruments Co., Malvern, UK).

The liposomal EGCG concentration was about 900 µg/mL, corresponding to an encapsulation efficiency of over 80%. Liposomes vesicles had a mean size of 170 nm, and the polydispersity values were lower than 0.2, showing that the vesicles are uniform and have the appropriate size for prolonged blood circulation. Additionally, the zeta potential was -51.83 mV, which ensures a good aggregative stability.

**Formalin test**

For nociception assessment, the formalin test was performed 4 h after NG administration [6]. The number of flinches and shakes were counted in 2 distinct phases: phase 1 (during 1 - 5 min) after subcutaneously formalin injection, and phase 2 (for 1 min period, at 5 min interval, during 10 - 60 min after formalin injection) [37]. These two distinct phases corresponding to the vasodilatory effect induced by noxious stimulus (phase 1) and inflammation onset (phase 2) [15].

**Oxidative stress and anti-oxidant parameters assessments**

For oxidative stress/antioxidant parameters assessment, blood samples were collected from the retro-orbital sinus at the end of the experiment, followed by animal euthanasia, by cervical dislocation (under ketamine anaesthesia 5 mg/100 g bw, i.p. route) [18]. Oxidative stress parameters assessed in this study consisted of malondialdehyde (MDA) assessment, the indirect assessment of nitric oxide synthesis (NOX), and the total oxidative status (TOS) of plasma measurement. MDA assessment was made by using thiobarbituric acid, as previously described [20]. Briefly, serum sample (150 µL), was mixed with trichloroacetic acid 40% (150 µL) and vortexed vigorously. Afterward, 300 µL 0.6 N 7% thiobarbituric acid was added, and all the components were kept at 95°C for 30 min, followed by ice cooling and centrifugation for 5 min at 13,000 rpm. The absorbance of each sample was determined at 530 nm compared with a blank [20]. NOX assessment was made by Griess reaction [10, 11]. In order to reduce the nitrate to nitrite 200 µL of deproteinated plasma sample was mixed with 200 µL of vanadium (III) chloride (VC13) (400 mg in 50 mL HCl 1 M) and further mixed with Griess reagent consisting in 50 mL sulphamidilamide solution (2 × 25 mL), 50 mL N-1-naphthylethylenediamine dihydrochloride (NED) solution (2 × 25 mL), 1 mL nitrite standard (0.1 M sodium nitrite). Each sample absorbance was measured after 45 min of incubation period (darkness medium, 37°C) at 540 nm. TOS measurement was made according to the method described by Erel [8]. The principle of the method is based on the proprieties of the oxidants present in the sample to oxidize the ferrous ion –o-dianisidine complex to ferric ion. For each sample, the procedure was as follows: 140 µL of the plasma was added to 900 µL of reagent 1 (contained 150 µM xylenol orange, 140 mM NaCl and 1.35 M glycerol in 25 mM H2SO4) and 44 µL of reagent 2 (contained 5 mM ferrous ammonium sulphate and 10 mM o-dianisidine dihydrochloride in 25 mM H2SO4). After were vortexed, the samples were incubated at room temperature for 30 min, and absorbance was measured at 560 nm. The total antioxidant capacity of plasma (TAC) and catalase measurements were used as parameters for antioxidative plasma status. TAC measurement was made following the method described by Erel [8]. Briefly, a mixture of 800 µL reagent 1 (R1), 20 µL serum sample and 40 µL reagent 2 (R2) was kept for 10 min at room temperature, followed by absorbance determination at 444 nm, compared with blank. R1 consists in xylenol orange 150 µM, NaCl 140 mM and glycerol 1.35 M in 25 mM H2SO4 solution, pH 1.75 and R2 contains ferrous ion 5 mM and o-dianisidine 10 mM in 25 mM H2SO4 solution. The results were expressed as mmol Trolox equivalents/L (TX Eq/L). Catalase was measured by the method described by Aebi that measures the catalase activity from the decomposition of H2O2 [1]. The decomposition of H2O2 was measured by the decrease in extinction at 240 nm. The difference in extinction per unit time is a measure of the catalase activity. Briefly, 2000 µL of potassium phosphate buffer (50 mM) was mixed with 10 µL H2O2, followed by absorbance sample determination at 240 nm (A1). After adding 10 µL serum from sample the second absorbance (A2) is assessed after 1 min. The catalase activity is expressed as U/L and is calculated from formula: (A2-A1) × (sample total volume)/d × V (where d is H2O2 extinction coefficient and is equal with 0.0436 mM, d = recipient width and is equal with 1 cm, and V is serum sample volume). All the spectrophotometrical measurements were made using a Jasco V-350 UV-VIS spectrophotometer (Jasco International Co, Ltd, Tokyo, Japan).

**Statistical analyses**

Data were analysed with Statistix10 program (Analytical Software, FL, USA), and presented as mean ± standard deviation. Individual data (circles) and the value of the median (line) were plotted to present the trends between investigated groups. The differences between groups were tested with two-sided Mann-Whitney, and P < 0.05 was considered statistically significant.

**Results and Discussion**

In this study, an experimental migraine model was induced in rats by i.p. administration of NG, a NO donor able to induce migraine and hyperalgesia in rats. Further, the ability of MC administrated alone or co-administered with EGCG in solution or liposomal form, to influence the oxidative/antioxidant balance and nociception, was assessed. The oxidative stress parameters and antioxidant status were evaluated, and the results are presented in Table I, Figures 1 and 2.
Administration of NG produced a significant change of all oxidative stress and antioxidant parameters (P < 0.001) (Table II). MC administration reduced the oxidative stress parameters but not the antioxidants (catalase and TAC), and the most relevant effect was noted on NOx concentration (P < 0.001). Co-administration of EGCG significantly changed oxidative stress and antioxidant parameters (MDA, TOS, and TAC), compared with the group with MC treatment alone. NOx and catalase level were not significantly reduced by co-administration of EGCG and MC (Table I, Figures 1 and 2). Moreover, L-EGCG succeeded to significantly reduce oxidative stress parameters, compared with MC alone or MC associated with EGCG solution (Table I, Figure 1). By L-EGCG administration, the best results were obtained for all the oxidative stress parameters among all treated groups, while the catalase level was the least affected from all studied parameters (Table I, Figure 2).

### Table I

<table>
<thead>
<tr>
<th>Parameter</th>
<th>C group</th>
<th>NG group</th>
<th>NG+MC group</th>
<th>NG+MC+EGCG group</th>
<th>NG+MC+L-EGCG group</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDA (pmol/L)</td>
<td>2.44 ± 0.11</td>
<td>5.79 ± 0.14</td>
<td>5.58 ± 0.11</td>
<td>5.26 ± 0.12</td>
<td>4.22 ± 0.11</td>
</tr>
<tr>
<td>NOx (µmol/L)</td>
<td>16.21 ± 0.76</td>
<td>48.54 ± 2.54</td>
<td>42.94 ± 1.40</td>
<td>42.24 ± 1.82</td>
<td>34.24 ± 1.39</td>
</tr>
<tr>
<td>TOS (µmol/L)</td>
<td>25.51 ± 1.27</td>
<td>48.14 ± 1.26</td>
<td>45.55 ± 1.23</td>
<td>42.43 ± 1.29</td>
<td>37.05 ± 1.20</td>
</tr>
<tr>
<td>Catalase (U/mL)</td>
<td>2.0 ± 0.04</td>
<td>1.74 ± 0.10</td>
<td>1.74 ± 0.08</td>
<td>0.88 ± 0.10</td>
<td>1.15 ± 0.06</td>
</tr>
<tr>
<td>TAC (mmol Tx Eq/L)</td>
<td>1.4 ± 0.04</td>
<td>0.74 ± 0.10</td>
<td>0.74 ± 0.08</td>
<td>0.88 ± 0.10</td>
<td>1.15 ± 0.06</td>
</tr>
</tbody>
</table>

**Figure 1.**

Distribution of oxidative stress intensity by groups: (a) MDA (malondialdehyde), (b) NOx (nitric oxide), (c) TOS (total oxidative status). The horizontal line is given by the median, and the circles represent the individual values. C = Control group; NG = NG control group with nitroglycerine i.p. administration; NG+MC = NG plus metoclopramide i.p. administration group; NG+MC+EGCG = NG plus MC co-administered with epigallocatechin gallate solution by i.p. route; NG+MC+L-EGCG = NG plus MC co-administered with liposomal-EGCG by i.p. route. The letter-number codes correspond to the p-values as follows: C compared to NG: \(a_1 < 0.001\); NG+MC compared to NG: \(b_1 < 0.001, b_2 < 0.001, b_3 < 0.001\); NG+MC+EGCG compared to NG: \(c_1 < 0.001, c_2 < 0.001, c_3 < 0.001\); NG+MC+L-EGCG compared to NG: \(d_1 < 0.001\); NG+MC+EGCG compared to NG+MC: \(x_1 < 0.001, x_2 > 0.236, x_3 < 0.001\); NG+MC+L-EGCG compared to NG+MC: \(y_1 < 0.001\); NG+MC+EGCG compared to NG+MC+L-EGCG: \(z_1 < 0.001\).
All of these molecules that contribute to the pain necrosis fact leukin the receptors for pro inflammatory cytokines like interleukin-1 (IL-1) [17], decreasing the expression of tumour necrosis factor-alpha (TNF-α) [19], or IL-6 and IL-8 [22]. All of these molecules that contribute to the pain pathophysiology, are suppressed due to the ability of EGCG to inhibit the NF-κB translocation, an important contributor to the expression of pro-inflammatory molecules [22]. In addition to its properties to reduce the pro-inflammatory cytokines, EGCG proved to reduce also the prostaglandins synthesis as PGE2, due to inhibition of cyclooxygenase-2 (COX2) expression, the intermediating mechanism being the inhibition of NF-κB translocation [14]. Due to its properties, EGCG is intensively studied together with other natural compounds as curcumin, resveratrol, capsaicin, quercetin, eugenol or naringenin, proving not only anti-inflammatory properties that can contribute to pain reduction, but also neuro-modulatory activities [34]. The effect of EGCG on oxidative stress, that is an inducer of inflammatory reaction, was already demonstrated [25]. Moreover, due to its anti-oxidant effects, its able to exert a neuroprotective effect [16]. Our results are in accordance with all of these findings, showing a significant reduction of nociception in experimental migraine (Table II, Figure 3) due to EGCG ability to reduce the oxidative stress parameters with MC, L-EGCG succeeded to have the most important effect, reducing of the numbers of flinches and shakes (Figure 3). In phase 2, only L-EGCG co-administered with MC significantly reduced the number of flinches and shakes compared with both control group or with the group treated with MC alone (Figure 3).

The formalin test - results by groups (number of flinches and shakes expressed as mean ± standard deviation)

<table>
<thead>
<tr>
<th>Phase</th>
<th>C group</th>
<th>NG group</th>
<th>NG+MC group</th>
<th>NG+MC+EGCG group</th>
<th>NG+MC+L-EGCG group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 1</td>
<td>20.14 ± 1.45</td>
<td>41.42 ± 1.59</td>
<td>33.85 ± 1.55</td>
<td>28.85 ± 1.88</td>
<td>24.85 ± 1.2</td>
</tr>
<tr>
<td>Phase 2</td>
<td>114 ± 3.33</td>
<td>151.57 ± 3.84</td>
<td>127.42 ± 3.15</td>
<td>125.42 ± 3.88</td>
<td>118.71 ± 2.65</td>
</tr>
</tbody>
</table>

Regarding the antinociceptive effect, for phase 1, comparing the control group with NG administration group, the number of flinches and shakes were significantly increased (P < 0.001) in NG group, being consistently reduced by MC administration alone or in combination with EGCG or L-EGCG (Table II, Figure 3). Comparing various treatments co-administered with MC, L-EGCG succeeded to have the most important effect, reducing of the numbers of flinches and shakes (Figure 3). In phase 2, only L-EGCG co-administered with MC significantly reduced the number of flinches and shakes compared with both control group or with the group treated with MC alone (Figure 3).
Formalin test results: (a) Phase 1 and (b) Phase 2 by groups. The horizontal line is given by the median, and the circles represent the individual values.

C = Control group; NG = NG control group with nitroglycerine i.p. administration; NG+MC = NG plus metoclopramide i.p. administration group; NG+MC+EGCG = NG plus MC co-administered with epigallocatechin gallate solution by i.p. route; NG+MC+L-EGCG = NG plus MC co-administered with liposomal-EGCG by i.p. route. The letter-number codes correspond to the p-values as follows: C compared to NG: $^{a,b,c}<0.001$; NG+MC compared to NG: $^{a,b,c}<0.001$; NG+MC+EGCG compared to NG: $^{b,c}<0.001$; NG+MC+L-EGCG compared to NG: $^{b,c}<0.001$; NG+MC+EGCG compared to NG+MC: $^{c}<0.001$; NG+MC+L-EGCG compared to NG+MC: $^{c}<0.001$; NG+MC+EGCG compared to NG+MC+L-EGCG: $^{c}<0.001$; NG+MC+L-EGCG compared to NG+MC+L-EGCG: $^{c}<0.001$; NG+MC+L-EGCG compared to NG+MC+L-EGCG: $^{c}<0.001$.

Conclusions

The results of our study evidenced that liposomal encapsulation of EGCG enhances the antinociceptive effect of MC. Thus, nanotechnology can significantly improve the therapeutic strategies for migraine patients. The difference between EGCG solution and L-EGCG is encouraging and could bring a valuable benefit in migraine therapy. These effects have to be tested in clinical studies in order to bring evidence for their application in migraine treatment. Our results can constitute a hope for improving the symptoms of migraine patients with L-EGCG as adjuvant therapy.

References